Laboratorios Farmaceuticos Rovi

The future of Rovi is very uncertain, we must wait until the year 2026 to have a clear projection.

kapirey

Not Invested

Community Contributor

Published

02 May 24

Updated

26 Jul 25

kapirey's Fair Value

€51.25

10.4% overvalued

26 Jul

€56.60

-21.6%

-3.5%

-21.6%

-3.5%

You can edit this narrative until Jul 26 7:05 PM. Then, changes will post as Updates.

Author's Valuation

€51.25

10.4% overvalued

kapirey's Fair Value

Narrative

Updates1

Shared on26 Jul 25
Fair value Decreased 14%

kapirey'sFair Value

€51.25

10.4% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.63%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.49%

Calculation

€168.07m

Earnings '30

24.00x

PE Ratio '30

€4.03b

Market Cap '30

€4.03b

Market Cap '30

51.15m

No. shares '30

€78.86

Share Price '30

€78.86 Share Price '30

Discounted to 2025 @ 9.00% p.a.

€51.25

Fair Value '25

The future of Rovi is very uncertain, we must wait until the year 2026 to have a clear projection.

Shared on26 Jul 25Fair value Decreased 14%

Shared on26 Jul 25
Fair value Decreased 14%